A significant finding emerges from a pooled prospective cohort analysis examining coffee consumption and survival outcomes in 5,442 colorectal cancer patients. Stage III patients who maintained the highest coffee intake demonstrated a striking 43% reduction in mortality compared to non-drinkers—a substantially larger benefit than observed across the entire study population.
When examined on a dose-response basis, Stage III patients experienced approximately 10% lower mortality for each additional daily cup of coffee consumed. The analysis incorporated data from four prospective cohort studies tracking post-diagnosis coffee intake and long-term survival outcomes. These findings suggest a particularly pronounced protective association in this intermediate-stage disease cohort. However, researchers underscore that validation in additional populations and further mechanistic investigation are essential before translating these observational findings into clinical recommendations.
Read the full article on GMJ Newsroom.
Was this article helpful?
